Outcome of Board Meeting held on May 20, 2026 as per SEBI (LODR) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts more than Nifty Microcap 250 and 4.3 pts more than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
MedPlus Health Services Limited reported strong FY2026 results with consolidated revenue growing 12.3% to Rs 68,924.66 million and profit after tax jumping 46.2% to Rs 2,196.06 million. Standalone revenue rose 20.7% to Rs 8,605.66 million with PAT up 54.7% at Rs 624.12 million. Basic EPS improved to Rs 18.33 (consolidated) and Rs 5.21 (standalone). The board approved allotment of 82,419 equity shares under ESOP 2021, taking paid-up capital to Rs 240.11 million. Two independent directors completed their tenure and two new ones were appointed. The managing director was re-appointed for five years. The company secretary resigned. Statutory auditors B S R and Co issued an unmodified (clean) opinion on both standalone and consolidated financial statements.
Strong financial performance with double-digit revenue growth and near 50% PAT growth indicates healthy business momentum. The clean audit opinion with no going concern issues is positive for investor confidence. Management changes and ESOP allotments suggest continuity in leadership and employee retention focus.